Premium
Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45‐month follow‐up of a prospective, randomized clinical trial
Author(s) -
Hubay Charles A.,
Pearson Olof H.,
Marshall James S.,
Rhodes Robert S.,
Debanne Sara M.,
Rosenblatt Judah,
Mansour Edward G.,
Hermann Robert E.,
Jones James C.,
Flynn William J.,
Eckert Charles,
McGuire William L
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801215)46:12+<2805::aid-cncr2820461413>3.0.co;2-h
Subject(s) - medicine , antiestrogen , breast cancer , oncology , chemotherapy , adjuvant , immunotherapy , estrogen receptor , mastectomy , tamoxifen , adjuvant therapy , stage (stratigraphy) , randomized controlled trial , cancer , gynecology , paleontology , biology
The results of adjuvant chemotherapy (CMF), endocrine therapy (t), and immunotherapy (BCG) in 318 women who had undergone mastectomy for Stage II breast cancer are reported after 45 months of life table analysis. CMFT therapy was found to be more effective than CMF alone in increasing recurrence‐free survival. This beneficial effect appears to be limited to patients with estrogen receptor‐positive tumors (ER+). Patients with estrogen receptor‐negative tumors (ER‐) (<3 fmol/mg) have increased recurrence rates and higher mortality.